Bocom International good prospects, recommended global health care-coreldraw快捷键大全

Bocom international outlook: recommended global medical hot column capital flows thousands of thousands of stocks the latest Rating Rating diagnosis simulated trading client sina finance App: Live on-line blogger to tutor Sina Hong Kong APP: real time market exclusive reference stocks also worth the investment? What’s the problem? Where is the future? Sina Hong Kong stocks launched "Hong Kong stocks are not attractive" big discussion, with a rational and constructive attitude, welcome to pay attention to Hong Kong stocks, people concerned about the capital market, together with Hong Kong stocks for advice and suggestions, and conspiracy of Hong Kong stock market tomorrow. Please to hkstock_biz@sina. Li Bo: non trading roadshow minutes and our initial idea of the valuation of new hospital operations, we have a preliminary idea of global healthcare new hospital business valuation.   according to our assumptions and models (see chart 1), we believe that the company’s new hospital operations are valued at approximately HK $9 billion 160 million to HK $12 billion 950 million.   it is worth noting that the new valuation is based on our assumptions and should be considered after the project is landed. Shares have risen by 13.5% since we released the next Phoenix report. Since the release of the next Phoenix report in September 2, 2016, the share price of global health care has soared by 13.5%. We reiterate our views on the company as follows: (I) the change of valuation system; (II) the dominant position of major shareholders; (III) more hospital cooperation expectations; and (IV) the effect of resource integration. (both) go into Sina Finance shares 交银国际:前景向好 推荐环球医疗 热点栏目 资金流向 千股千评 个股诊断 最新评级 模拟交易 客户端 新浪财经App:直播上线 博主一对一指导 新浪港股APP:实时行情 独家内参   港股还值不值得投资?出现了什么问题?未来出路在哪里?新浪港股发起“港股还有没有吸引力”大讨论,以理性、建设性的态度,欢迎关注港股、关注资本市场的人士,一起为港股建言献策,共谋港股市场的明天。来稿请至hkstock_biz@sina 。   李博﹕非交易路演纪要和我们对新医院业务估值的初步想法我们对环球医疗新医院业务估值的初步想法。    根据我们的假设和模型(见图表1),我们认为公司的新医院业务估值约为91.6亿港元至129.5亿港元。 值得注意的是,新增估值乃基于我们的假设来计算,应当在项目落地后予以考虑。自我们发布‘下一只凤凰’报告以来,股价已上升13.5%。   自我们于2016年9月2日发布‘下一只凤凰’报告以来,截至昨日环球医疗的股价已飙升13.5%。我们重申对公司的看法如下:(i)估值体系的转变;(ii)大股东的优势地位;(iii)更多的医院合作预期;及(iv)资源整合效应。(双双) 进入【新浪财经股吧】讨论相关的主题文章:

About hanson 9183 Articles